La rete informatica del Paese creata per targetizzare le terapie oncologiche

  • Segretario

    Luca Mazzarella


  • Coordinatore Wet

    Simonetta Buglioni


  • Coordinatore Bioninformatico

    Giovanni Tonon


ACC, an organization which unites some of the most important Italian research institutes involved in landmark translational studies, has set up working groups to focus on single pathologies whose matrix is the Genomics WG, a research platform that crosscuts the other clinical research groups and which was set up to make molecular analysis technologies more easily accessible to researchers in the Network.

The national IT infrastructure, that is coordinated by a team of bioinformatics scientists based at the European Institute of Oncology (IEO) in Milan, is central to the WG – lead by Luca Mazzarella of the IEO. The team oversees the work of the researchers from each ACC associated Institute. In fact, in every Centre there is a bioinformatics scientist and a wet biologist who are responsible for processing, analysing and then transferring the data obtained from clinical trials to the national computational platform. This data is then integrated with information from scientific literature in order to set up databases, which are equipped with a user-friendly interface, that oncologists can use to select the most appropriate treatment according to the molecular profile of the Patient’s tumour.

The future work of the Working Group will be oriented in three main directions: firstly towards optimizing collaboration within the Network as well as interaction with pharmacology research stakeholders as it is clear that if the use of breakthrough technologies for the molecular characterization of individuals is not matched with a wide range of tailored drugs, all efforts will have been in vain; secondly, and ever more importantly, towards integrating the various methods of molecular analysis – point mutations, increase in sensitivity for structural variants, use of gene expression data and advanced technologies, such as RNA Sequencing  and the sequencing of specific aspects of tumour biology; lastly, towards the development of technologies for the analysis of circulating DNA (liquid biopsy) that will allow analysis of large mutation panels as well as, for example, the metabolomic or proteomic analysis of blood. One of the main obstacles to implementing precision medicine, which is the continual request for Patients’ bioptic material, will thus be overcome.

Il Team

  • Bioinformatici
  • Wet